Item 8.01 Other Events
On December 9, 2019, Quest Diagnostics Incorporated (the "Company") issued a
press release announcing the pricing of a public offering of $800 million
aggregate principal amount of its 2.950% senior notes due 2030 (the "Notes")
under the Company's shelf registration statement.
The Company expects to receive the net offering proceeds upon closing on
December 16, 2019, subject to customary closing conditions. The Company intends
to use the net proceeds from the offering to repay at maturity or redeem its
4.750% senior notes due 2020 and 2.500% senior notes due 2020 and for general
corporate purposes. This Current Report on Form 8-K is not a notice of
redemption. Any notice of redemption will be made in accordance with the
applicable provisions of the indenture governing such notes. A copy of the press
release, dated December 9, 2019, is attached to this Current Report on Form 8-K
as Exhibit 99.1 and is incorporated by reference into this Current Report on
Form 8-K.
In connection with the offering of the Notes, on December 9, 2019, the Company
entered into an underwriting agreement (the "Underwriting Agreement") with J.P.
Morgan Securities LLC, Morgan Stanley & Co. LLC and Wells Fargo Securities, LLC
on behalf of themselves and the other underwriters named therein. The
Underwriting Agreement is attached to this Current Report on Form 8-K as Exhibit
1.1 and is incorporated by reference into this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits
Exhibit Description
1.1 Underwriting Agreement, dated December 9, 2019.
99.1 Press Release issued by the Company, dated December 9, 2019,
announcing pricing of notes.
104 The cover page from this current report on Form 8-K, formatted
in Inline XBRL.
© Edgar Online, source Glimpses